Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Explore how biotech breakthroughs in 2024 have changed lives, bringing real Christmas miracles to patients and offering hope ...

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated risk of mortality in its ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...

Peptides, short chains of amino acids, have been extensively studied for their potential role in mitigating bone degradation.

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Developed in-house, BAY3498264 addresses the unmet medical need of improving efficacy of treatment targeting the mitogen-activated protein kinase (MAPK) signalling pathway which regulates cell ...